Sugi Predict

Sugi Predict / Compounds / SCHEMBL940424

SCHEMBL940424

SCHEMBL940424

CCOC(=O)N1CCc2[nH]c3ccccc3c2C1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.74
▸ ATM Q13315 2/20 0.74
▸ PABPC1 P11940 1/20 0.74
▸ SMN1; SMN2 Q16637 1/20 0.74
▸ MAPT P10636 4/20 0.70
▸ BAZ2B Q9UIF8 2/20 0.70
▸ KMT2A Q03164 4/20 0.64
▸ TAAR1 Q96RJ0 1/20 0.61
▸ ALDH1A1 P00352 5/20 0.58
▸ KDM4E B2RXH2 4/20 0.58
▸ CASP1 P29466 3/20 0.58
▸ CASP7 P55210 2/20 0.58
▸ MEN1 O00255 2/20 0.57
▸ ALOX15 P16050 2/20 0.57
▸ FAAH O00519 2/20 0.57
▸ TRPV1 Q8NER1 2/20 0.57
▸ GAA P10253 1/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11756202 0.88 SMN1; SMN2 (0.58) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL24405315 0.87 MAPT (0.74) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL12868460 0.87 MAPT (0.62) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL407460 0.85 LMNA (1.00) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL29466250 0.84 MAPT (0.66) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL29357331 0.84 MAPT (0.69) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL2241936 0.84 MAPT (0.69) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL12127702 0.83 LMNA (0.69) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL10777655 0.83 SMN1; SMN2 (0.79) LMNAATMPABPC1SMN1; SMN2MAPT
SCHEMBL764099 0.83 LMNA (0.79) LMNAATMPABPC1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2022-12-01 — — US disclosed
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2022-12-01 — — US disclosed
US-11420967-B2 Modified carbazoles as therapeutic agents UNIVERSITY OF WASHINGTON (US) 2022-08-23 — — US disclosed
CN-110698474-B Alpha-substituted tetrahydro-gamma-carboline compound and preparation method and application thereof 福州大学 2021-11-02 — — CN disclosed
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2021-04-01 — — US disclosed
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS THE UNIVERSITY OF MONTANA 2021-04-01 — — US disclosed
CN-110698474-A Alpha-substituted tetrahydro-gamma-carboline compound and preparation method and application thereof 福州大学 2020-01-17 — — CN disclosed
EP-3013824-B1 CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ALZPROTECT (FR) 2018-05-16 — — EP disclosed
US-9822092-B2 ArylSulfonamide-based matrix metalloprotease inhibitors NOVARTIS AG (CH) 2017-11-21 — — US disclosed
US-9714245-B2 Carboline compounds usable in the treatment of neurodegenerative diseases ALZPROTECT (FR) 2017-07-25 — — US disclosed
US-8222424-B2 Arylsulfonamide-based matrix metalloprotease inhibitors NOVARTIS AG (CH) 2012-07-17 — — US disclosed
US-20110014186-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2011-01-20 — — US disclosed
EP-0902684-B1 HEXAHYDRO-PYRIDO(4,3-B)INDOLE DERIVATIVES AS ANTIPSYCHOTIC DRUGS JANSSEN PHARMACEUTICA NV (BE) 2003-04-09 — — EP disclosed
US-6057325-A HAVE CENTRAL DOPAMINE AND SEROTONIN ANTOGONISTIC ACTIVITY JANSSEN PHARMACEUTIA, N.V. (BE) 2000-05-02 — — US disclosed
EP-0716661-B1 PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS SCIOS INC (US) 2000-04-05 — — EP disclosed
EP-0902684-A1 HEXAHYDRO-PYRIDO(4,3-B)INDOLE DERIVATIVES AS ANTIPSYCHOTIC DRUGS JANSSEN PHARMACEUTICA N.V. (BE) 1999-03-24 — — EP disclosed
US-5817756-A USING A MODIFIED DI- OR TRI-PEPTIDES SCIOS INC. (US) 1998-10-06 — — US disclosed
WO-1997044040-A1 HEXAHYDRO-PYRIDO(4,3-B)INDOLE DERIVATIVES AS ANTIPSYCHOTIC DRUGS JANSSEN PHARMACEUTICA N.V. (BE) 1997-11-27 — — WO disclosed
EP-0716661-A1 PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS SCIOS NOVA INC. (US) 1996-06-19 — — EP disclosed
WO-1995007294-A1 PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS SCIOS NOVA INC. (US) 1995-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380367-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, TUBA1C LMNA 1313/4885ATM 609/4885PABPC1 1421/4885
US-20210094949-A1 MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, TUBA1C LMNA 1313/4885ATM 609/4885PABPC1 1421/4885
US-20110014186-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS MMP11, MMP10, MMP9 LMNA 2167/4885ATM 2636/4885PABPC1 4760/4885
US-11420967-B2 Modified carbazoles as therapeutic agents TUBB3, TUBB1, TUBA1C LMNA 1313/4885ATM 609/4885PABPC1 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.